Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nadofaragene firadenovec - FKD Therapies

X
Drug Profile

Nadofaragene firadenovec - FKD Therapies

Alternative Names: AAV-IFN-apha-2b-gene-therapy-FKD-Therapies; Adenovirus-Delivered Interferon Alpha-2b; Adstiladrin; FE-999326; Instiladrin; Nadofaragene firadenovec-vncg; Nadofaragene firadenovec/Syn3; rAd-IFNα; rAd-IFNα/Syn3; SCH-209702/SCH-721015; SCH-721015; SCH-721015/SCH-209702; TR-002

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Ferring Pharmaceuticals; FKD Therapies; Trizell; University of Pennsylvania
  • Class Antineoplastics; IFNA2B gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; IFNA2B expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer
  • Phase III Malignant-mesothelioma

Most Recent Events

  • 06 May 2024 Efficacy and adverse events data from phase III trial in Bladder cancer released by Ferring Pharmaceuticals
  • 16 Apr 2024 Phase-II clinical trials in Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intravesicular)
  • 16 Apr 2024 Phase-III clinical trials in Bladder cancer in USA (Intravesicular)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top